Please login to the form below

Not currently logged in
Email:
Password:

PfSPZ

This page shows the latest PfSPZ news and features for those working in and with pharma, biotech and healthcare.

Dosing of GSK's malaria vaccine due to start in 2018

Dosing of GSK's malaria vaccine due to start in 2018

Another malaria vaccine developed by US biopharma company Sanaria – called PfSPZ – has been shown to offer improved protection rates, possibly as high as 80%, as well as a duration of action

Latest news

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    The PfSPZ vaccine had previously been shown to provide a short-term immunological response targeted at the malaria parasite, but in the latest trial was shown to provide protection against infection ... Sanaria chief executive Stephen Hoffmann said that

  • Scientists finds new drug target for malaria Scientists finds new drug target for malaria

    In August NIV researchers said they had achieved "unprecedented" results in a small study of a weakened, live Plasmodium falciparum vaccine called PfSPZ.

  • GSK hoping to file malaria vaccine next year GSK hoping to file malaria vaccine next year

    In the summer, researcher at the US National Institutes of Health (NIH) reported encouraging early clinical of another candidate called PfSPZ - in development at small US biotech Sanaria - which provided complete

  • Malaria vaccine gives Malaria vaccine gives "unprecedented" results

    At the highest dose tested, vaccination with the PfSPZ shot provided complete protection against malaria in six patients. ... The researchers found that participants who received a higher total dosage of PfSPZ generated more antibodies against malaria

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics